Please login to the form below

Not currently logged in
Email:
Password:

sembragiline

This page shows the latest sembragiline news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Last year Roche and Evotec's sembragiline failed a phase II trial and Pfizer this week announced it has halted development of its candidate, PF-05212377, after it too failed to

Latest news

  • Roche and Evotec’s Alzheimer’s drug ineffective Roche and Evotec’s Alzheimer’s drug ineffective

    Roche and Evotec’ s Alzheimer’ s drug ineffective. Sembragiline failed to show cognitive and memory benefits. ... Roche reports that sembragiline – a drug in the monoamine oxidase type B (MAO-B) inhibitor class – was unable to show a significant

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics